ArticleInvestigational new drugs2024

A phase 1b study of the ERK inhibitor MK-8353 plus pembrolizumab in patients with advanced solid tumors.

Nehal J Lakhani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.